Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation

NCT01848093 | Withdrawn

• 1 other identifier: 160/08
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 2

Brief Summary

chronic obstructive pulmonary disease (COPD) is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study the investigators found that mucins are decreased and unstable in the sputum of adult cystic fibrosis (CF) patients. In this study the investigators want to investigate the differences on the mucin quantity and quality of airway secretions during pulmonary exacerbation of patients with COPD.

Conditions

COPD

Keywords

lung; airway; pulmonary exacerbation; mucus

Outcome Measures

Primary Outcomes (1)

• mucin concentration

  analyzing mucin concentration by western

  2 month

Secondary Outcomes (1)

• mucin stability

  2 month

Study Arms (1)

COPD exacerbation

COPD Stadium 2 and 3 during pulmonary exacerbation sputum collection

Other: sputum collection

Interventions

sputum collection OTHER

collecting of spontaneous sputum from the patient

COPD exacerbation

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

COPD patients Stadium 2-3 during pulmonary exacerbation

You may qualify if:

• forced expiratory volume at one second (FEV1) \< 80%
• sputum production
• clinical likely hood of exacerbation

You may not qualify if:

• FEV1 \> 80% or \< 30%
• increased systemic inflammation
• susceptibility of pneumonia
• need for antibiotic treatment

Sponsors & Collaborators

• Philipps University Marburg: lead

Study Sites (2)

pulmonary department, University Marburg

Marburg, 35043, Germany

Location

University Marburg

Marburg, Germany

Location

Related Publications (3)

• Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91. doi: 10.1165/rcmb.2003-0345OC. Epub 2004 Feb 26.

  PMID: 14988081 BACKGROUND

• Henke MO, John G, Rheineck C, Chillappagari S, Naehrlich L, Rubin BK. Serine proteases degrade airway mucins in cystic fibrosis. Infect Immun. 2011 Aug;79(8):3438-44. doi: 10.1128/IAI.01252-10. Epub 2011 Jun 6.

  PMID: 21646446 BACKGROUND

• Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med. 2007 Apr 15;175(8):816-21. doi: 10.1164/rccm.200607-1011OC. Epub 2007 Jan 25.

  PMID: 17255563 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

sputum

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Markus Henke, MD

  University Marburg

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2013
• First Posted: May 7, 2013
• Study Start: December 1, 2008
• Primary Completion: June 1, 2013
• Study Completion: July 1, 2013
• Last Updated: November 15, 2016

Record last verified: 2013-05

Locations

DE (2)